Why are patients with renal failure at increased risk for aluminum toxicity?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

Why are patients with renal failure at increased risk for aluminum toxicity?

Explanation:
Aluminum is eliminated primarily by the kidneys, so when kidney function is impaired, aluminum clearance drops and its body burden rises. In renal failure, even small ongoing exposures—such as from IV solutions, medications like phosphate binders, or components of parenteral nutrition—can accumulate, increasing the risk of toxicity. This can manifest as bone disorders, anemia, and neurological effects like encephalopathy. The other statements aren’t accurate because aluminum is not mainly cleared by the liver, it can be excreted and accumulate with exposure, and modern PN components can still contain aluminum despite efforts to minimize it.

Aluminum is eliminated primarily by the kidneys, so when kidney function is impaired, aluminum clearance drops and its body burden rises. In renal failure, even small ongoing exposures—such as from IV solutions, medications like phosphate binders, or components of parenteral nutrition—can accumulate, increasing the risk of toxicity. This can manifest as bone disorders, anemia, and neurological effects like encephalopathy. The other statements aren’t accurate because aluminum is not mainly cleared by the liver, it can be excreted and accumulate with exposure, and modern PN components can still contain aluminum despite efforts to minimize it.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy